Sponsors
Bioprojet was established in order to bring academic research closer to industrial pharmaceutical development, a practice that was not very widespread 1982. We have one objective: to apply ourselves to original work in basic research in order to design and develop drugs which are the first of their kind in new therapeutic classes. Bioprojet is comprised of Bioprojet PHARMA, responsible for the development and marketing of medicines and Bioprojet BIOTECH which oversees all of the group’s R&D. Today we provide pharmaceutical research in neurology, gastro-enterology, allergology, oncology & cardio-pneumology.
Nox Medical is a global leader in the sleep diagnostic technology space. We provide sleep specialists with patient-friendly diagnostic devices and robust, reliable data collection. With easy-to-use medical device technology, Nox Medical eliminates common diagnostic pain points by prioritizing patient comfort and reliability of results, allowing providers to better assess, diagnose and treat the entire range of sleep health issues, including sleep apnea, circadian disorders and insomnia.
Key product lines include Nox A1s PSG system, Nox T3s home sleep test, Nox SAS solution, and Noxturnal single platform software.
Takeda Neuroscience is driven by the unmet needs of patients with rare neurological diseases. Our mission is to bring innovative and potentially disease-modifying medicines to these patients. To deliver on this mission, our approach leverages advances in molecularly and genetically defined targets, biomarkers, and targeted modalities. Our commitment to patients is focused on our goal of developing new treatments for those who need them most.
Idorsia is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
At Philips, we offer connected care solutions that streamline processes and drive efficiencies so providers can administer efficient and effective patient care. Our innovative solutions connect data, technology and people across the care continuum to provide safe and effective therapy in sleep and respiratory care. For the past 40 years, we have centered our business around our commitment to patient care, with solutions that are aimed at improving the lives of people with respiratory and sleep challenges.
At ResMed, we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries.
VIVISOL, a company part of SOL Group, has been active for over 35 years in homecare services. VIVISOL services cover many therapeutic areas, including respiratory care, nursing, infusion therapies, advanced homecare, home dialysis, and assistive devices development, production, and distribution.
NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex CNS disorders. We have recently completed a phase 2 study in the US in adult subjects with narcolepsy with its lead asset, a proprietary extended-release formulation of mazindol (mazindol ER). Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist.
Avadel Pharmaceuticals plc is focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options.